bG-CSF Formulation Stability via Surfactant Extraction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional methods for developing pharmaceutical formulations of bovine Granulocyte Colony Stimulating Factor (bG-CSF) result in undesirable product properties such as aggregation and destabilization of the bG-CSF polypeptide and/or the formulation.
Innovation Solution
The development of stable aqueous pharmaceutical formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, with the formulation being substantially free of polyoxyethylene (20) sorbitan monolaurate, to minimize product aggregation and destabilization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If traditional surfactants are included in hG-CSF formulations to protect against destabilizing interfaces, then conformational stability is improved, but aggregation and destabilization of bG-CSF occur
Solution Approach 1:
The patent removes traditional surfactants (polysorbates) from the formulation and replaces them with a novel surfactant system comprising a nonionic surfactant (e.g., polysorbate 80) at optimized low concentrations combined with a zwitterionic surfactant (e.g., lecithin). This extraction of the problematic traditional surfactant while introducing an alternative system resolves the contradiction by eliminating aggregation and destabilization while maintaining conformational stability protection.
Solution Approach 2:
The patent employs a composite surfactant system combining multiple surfactant types (nonionic and zwitterionic) with specific concentration ratios. This composite approach provides synergistic protection against interface-induced destabilization without causing the aggregation problems associated with traditional single-surfactant formulations, thereby resolving the technical contradiction between stability protection and aggregation prevention.
2Ease of manufacture
If traditional formulation methods are used for bG-CSF, then manufacturing process is simplified, but product aggregation and destabilization occur
Solution Approach 1:
The patent modifies key formulation parameters including surfactant type, concentration, and pH to achieve stable bG-CSF formulations. By optimizing these parameters (e.g., using specific nonionic and zwitterionic surfactant combinations at controlled concentrations, adjusting pH to specific ranges), the patent maintains ease of manufacture through straightforward formulation processes while eliminating aggregation and destabilization, thus resolving the contradiction between manufacturing simplicity and product reliability.
3Stability of the object's composition
If surfactants are used to protect bG-CSF at destabilizing interfaces, then conformational stability is improved, but product aggregation increases
Solution Approach 1:
The patent introduces a mediating surfactant system comprising nonionic and zwitterionic surfactants that act as intermediaries between bG-CSF and destabilizing interfaces. These surfactants adsorb at interfaces and prevent direct exposure of the protein to destabilizing environments, thereby maintaining conformational stability without inducing aggregation. The mediating action of the optimized surfactant system resolves the contradiction by providing stability protection while preventing aggregation.
Data Source
AI summary
This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides methods of using, a lyophilized or powdered form of, and processes for, preparing the formulation.